RE:Question Hey Mega
I don't really have a share price prediction ...
...it's whatever " they" would like it to be for whatever the purpose of the day is.
I have put up several "fair valuation" posts in the past, under the assumption of ultimate FDA approval.
If the Company was properly marketed, with better coverage on a better exchange ... then it would begin to drift towards it's true underlying "fair value" ( pre FDA but factoring in probabilities)
Otherwise a significant and fair SP may only be determined "all at once", in a " all-of-a-sudden" denouement event.
But I would think it reasonable to suggest that as the 90 Tigris patient mark nears (around end of the year), and Baxter steps up for payment # 2, even this "off-off-off-the-radar" play will begin to drift upwards. Particularly if the pace of enrolment continues to accelerate in the coming months (due to more sites being onboarded, new CRO, new momentum post Investigators-meeting, anticipation of hitting 150 as early as 2024 - assuming no stoppage at 90, etc.
Hope this helps
MM